The Ministry of Health and Welfare recently published the revised draft of the Administrative Measures for the Implementation or Use of Medical Devices for Specific Medical Technology Inspection (hereinafter referred to as the Special Administrative Measures). Autologous peripheral blood stem cell transplantation and autoimmune cell therapy, which cancer patients are most concerned about, are included in special management measures. After being approved and registered by medical institutions, patients who meet the indications can be treated with cell therapy. In order to welcome the new era of cancer immunotherapy, domestic academic circles and biotechnology industry jointly held an international symposium on cancer immunotherapy, and invited Dr. Kenichiro Lian Jian, a Japanese immunotherapy authority, to come to Taiwan to share the patent "therapeutic immunotherapy initiated by human beings" in cancer immunotherapy.
Industry, government and industry join hands to open a new era of tumor immune cell therapy
At present, the principles of immunotherapy can be divided into two categories. The first is to fight against foreign viruses, bacteria or abnormal cells, such as cancer cells, by enhancing the efficacy of the autoimmune system, which is initiated by the initiative in the body; The second is to send foreign antibodies or domesticated cells into the body, so that the immune system in the body can know the marks of these foreign substances and strengthen the recognition and elimination of cancer cells. Immunotherapy is developed according to these two principles. Immunotherapy, as an adjuvant therapy for cancer, has gradually matured in the world, and it is the most popular therapy besides targeted drugs in recent years. With the efforts of many parties, the Ministry of Health and Welfare is expected to submit the Special Administrative Measures to the Legislative Council for deliberation in late August and promulgate them in September.
Individualized anti-cancer therapy returning to autoimmunity
The treatment produced by regulating autoimmunity does not adopt extensive poisoning methods such as chemotherapy or targeted drugs. Immunotherapy is more accurate in identifying cancer cells, which is based on the autoimmune system, so there are fewer rejection reactions and lower side effects. More and more research has turned to immunotherapy. HITV therapy was invented by Kenichiro Lian Jian in 2005. This therapy is to train dendritic cells (DC) in immune cells into special forces with antigens on their own cancer cells, and then transfer these cancer cell recognition skills to cytotoxic T cells (CTL). These killer immune cells can quickly and accurately identify cancer cells in the body, and completely lock and eliminate them.
HITV combined with radiotherapy can improve immunity more accurately, eliminate tumor and prevent recurrence.
The combination of HITV therapy and radiotherapy and chemotherapy makes the effect of HITV therapy more exciting. There is also a combination of radiotherapy and chemotherapy in the treatment of HITV. IMRT conformal radiotherapy is used to accurately control the irradiation direction and intensity and minimize the damage to normal cells. Chemotherapy, on the other hand, targets the specific proliferation and metastasis molecules of cancer cells through patented "molecular targets" and other drugs. In addition, CTL cells induced by HITV, after fighting against cancer cells in vivo, will continue to transmit this cancer-killing skill in vivo, forming a huge information transmission network, shaping the body into a highly immune environment, reducing the recurrence rate and prolonging the remission period. Dr Lian Jian is looking forward to introducing this technology into Taiwan Province Province to help more cancer patients.
Join us and pay attention to your health every day! Line @ ID: @ Subscribe to the healthy Aloha audio-visual channel to read health knowledge more easily: /beauty/article/39009 Keywords: cancer, immunotherapy, Lianjianichiro, cell therapy, HITV therapy, special management measures.